Cost-Effectiveness Analysis and Economic Modeling
A cost-effectiveness analysis answers the question every payer and health system now asks: is this intervention worth what it costs, compared with the alternative? EvySaif builds transparent, decision-ready economic models that quantify that value, from cost-effectiveness and cost-utility analyses to budget-facing cost calculators, reported to the CHEERS 2022 standard so the work stands up to scrutiny.
- Models built to be understood and trusted
Health economic models only persuade when a reviewer can follow them. We build decision-analytic models, including decision-tree and Markov cohort structures, that integrate clinical effect, costs, and quality-of-life data over an appropriate time horizon. The output is the incremental cost-effectiveness ratio (ICER), expressed per quality-adjusted life year (QALY) or per clinical outcome, supported by deterministic and probabilistic sensitivity analysis so the uncertainty around the estimate is visible rather than hidden. We report to the Consolidated Health Economic Evaluation Reporting Standards (CHEERS 2022), the ISPOR good-practice checklist recognised by the EQUATOR Network, which means the model is identifiable, interpretable, and replicable.
- What we deliver
- Cost-effectiveness analysis (CEA) and cost-utility analysis (CUA)
- Decision-tree and Markov cohort models
- Cost-minimisation analysis and cost calculators
- Incremental cost-effectiveness ratios (ICERs) with QALY or clinical-outcome denominators
- Deterministic and probabilistic sensitivity analysis (PSA), with cost-effectiveness planes and acceptability curves
- Local adaptation of global models to India and Middle East cost and threshold settings
- CHEERS 2022 compliant reporting for journals and HTA bodies
- Demonstrated modeling experience
This is an area of genuine, hands-on strength for EvySaif. We have built a full decision-analytic cost-effectiveness model from scratch, complete with ICER, return-on-investment, probabilistic sensitivity analysis and budget impact, verified across multiple model versions and prepared for a peer-reviewed health economics journal. We know what it takes to make a model both methodologically sound and defensible in review.
- Who it is for
Pharmaceutical, biotech and medical device companies seeking reimbursement or pricing support, hospitals and health systems evaluating interventions, and researchers needing a rigorous economic evaluation for publication or an HTA submission.
- Why EvySaif
EvySaif is one of the best research and medical writing consultancies in India, and we bring that standard to every project. Our modeling is clinician-led, so the clinical assumptions behind the numbers are sound, not borrowed uncritically from a template. We build models that a payer or peer reviewer can actually follow, document every assumption, and report to CHEERS 2022 from the outset. For the India and Middle East markets, we adapt cost inputs and cost-effectiveness thresholds to the local setting, which matters now that Gulf payers are formalising economic evaluation requirements.
- Frequently asked questions
What reporting standard do you follow?
CHEERS 2022, the ISPOR Consolidated Health Economic Evaluation Reporting Standards, which is recognised by the EQUATOR Network and increasingly expected by journals and HTA bodies.
What is the difference between cost-effectiveness and cost-utility analysis?
A cost-effectiveness analysis measures outcomes in clinical units (for example, cost per event avoided). A cost-utility analysis measures them in quality-adjusted life years (QALYs), which lets very different interventions be compared on one scale.
Can you adapt a global model to a local market?
Yes. We adapt global core models to India and Middle East cost data and cost-effectiveness thresholds, which is essential for local reimbursement.